istock-936761078-marrio31

marrio31 / iStockphoto.com

20 November 2018Americas

LSPN Europe 2018: Russian litigation and US second medical use

The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer

19 November 2018 The UK has an excellent opportunity to adopt laws on supplementary protection certificates that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.

LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers

16 November 2018 Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.

More on this story

LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer

19 November 2018 The UK has an excellent opportunity to adopt laws on supplementary protection certificates that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.

LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers

16 November 2018 Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.

More on this story

LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer

19 November 2018 The UK has an excellent opportunity to adopt laws on supplementary protection certificates that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.

LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers

16 November 2018 Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility